{
    "companyName": "BioXcel",
    "documentType": "10-K/A",
    "fillingDate": "20221231",
    "text": "&#160;&#160;UNITED STATESSECURITIES AND EXCHANGE COMMISSION&#160;Washington, D.C. 20549&#160;&#160;&#160;FORM 10-K/A&#160;(Amendment No.&#160;1)&#160;&#160;&#160;(Mark one)&#120;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities ExchangeAct of 1934For the year endedDecember 31, 2022or&#168; &#160;&#160;&#160;&#160;&#160;&#160;&#160;Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities ExchangeAct of 1934For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#160;&#160;&#160;Commission file number 001-38410&#160;BioXcel Therapeutics, Inc.(Exact name of Registrant as specified in its charter)&#160; Delaware (State or other jurisdiction of incorporation or organization) &#160; 82-1386754 (I.R.S.&#160;Employer Identification No.) &#160; 555 Long Wharf Drive New Haven CT (Address of principal executive offices)&#160; 06511 (Zip Code) &#160; &#160;Registrant&#8217;s telephone number, includingarea code: (475) 238-6837&#160;Securities registered pursuant to Section&#160;12(b)of the Act:&#160; Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.001 per share BTAI Nasdaq Capital Market &#160;Securities registered pursuant to Section&#160;12(g)of the Act: None&#160;Indicate by check markif the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#168;No &#120;&#160;Indicate by check markif the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes &#168;No &#120;&#160;Indicate by check markwhether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) hasbeen subject to such filing requirements for the past 90 days. Yes &#120;No &#168;&#160;Indicate by check mark whetherthe registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submitsuch files). Yes &#120;No &#168;&#160;Indicate by check mark whetherthe registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerginggrowth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reportingcompany,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.&#160; Large accelerated filer &#168; Accelerated filer &#168; Non-accelerated filer &#120; Smaller reporting company &#120; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Emerging growth company &#120; &#160;If an emerging growth company,indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#120;&#160;Indicate by check mark whetherthe registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal controlover financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit report. &#168;&#160;If securities are registeredpursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements. &#168;&#160;Indicate by check mark whetherany of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any ofthe registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#168;&#160;Indicate by check mark whetherthe registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#168;No &#120; &#160;As of June&#160;30, 2022,the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;scommon stock held by non-affiliates of the registrant was approximately $250,888,981 (based upon the closing sale price of the registrant&#8217;scommon stock reported on the Nasdaq Capital Market on that date). This calculation excludes shares held by the registrant&#8217;s currentdirectors and executive officers and stockholders that the registrant has concluded are affiliates of the registrant.&#160;There were 29,009,536 sharesof our common stock outstanding at March&#160;13, 2023.&#160; Auditor Name &#160; Auditor Location &#160; Auditor Firm ID Ernst Young LLP &#160; Stamford, Connecticut &#160; 42 &#160;&#160; &#160; &#160; &#160;EXPLANATORY NOTE&#160;On March&#160;16, 2023, BioXcelTherapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 (&#8220;Original Form 10-K&#8221;).The Original Form 10-K omitted portions of Part III, Items&#160;10 (Directors, Executive Officers and Corporate Governance), 11 (ExecutiveCompensation), 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationshipsand Related Transactions, and Director Independence), and 14 (Principal Accountant Fees and Services) in reliance on General InstructionG(3) to Form 10-K, which provides that such information may be either incorporated by reference from the registrant&#8217;s definitiveproxy statement or included in an amendment to Form 10-K, in either case filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)not later than 120 days after the end of the fiscal year.&#160;We no longer expect that thedefinitive proxy statement for our 2023 annual meeting of stockholders will be filed within 120 days of December&#160;31, 2022. Accordingly,this Amendment No.&#160;1 to Form 10-K (&#8220;Amendment&#8221;) is being filed solely to:&#160;&#183;amend and restate Part III, Items 10, 11, 12, 13, and 14 of the Original Form 10-K to include the informationrequired by such Items;&#160;&#183;delete the reference on the cover of the Original Form 10-K to the incorporation by reference of portionsof our proxy statement into Part III of the Original Form 10-K; and&#160;&#183;file new certifications of our principal executive officer and principal financial officer as exhibitsto this Amendment under Item 15 of Part IV hereof, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (&#8220;ExchangeAct&#8221;). Because no financial statements are contained within this Amendment, we are not including certifications pursuant to Section&#160;906of The Sarbanes-Oxley Act of 2002.&#160;This Amendment does not otherwisechange or update any of the disclosures set forth in the Original Form 10-K and does not otherwise reflect any events occurring afterthe filing of the Original Form 10-K. Accordingly, the Amendment should be read in conjunction with the Original Form 10-K and the Company&#8217;sfilings made with the SEC subsequent to the filing of the Original Form 10-K. Capitalized terms used herein and not otherwise definedare defined as set forth in the Original Form 10-K.&#160;As used in this Annual Reporton Form 10-K, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221;the &#8220;Company&#8221; or &#8220;BTI&#8221; refer to BioXcel Therapeutics, Inc., and &#8220;BioXcel, LLC&#8221; refers to the Company&#8217;sformer parent company and significant stockholder, BioXcel LLC, and its predecessor, BioXcel Corporation. All brand names or trademarksappearing in this Annual Report on Form 10-K are the property of their respective owners, including IGALMI, which is a trademark of BioXcelTherapeutics, Inc.&#160; &#160; &#160; &#160;TABLE OF CONTENTS&#160;Page&#160; PART III 1 Item 10. Directors, Executive Officers, and Corporate Governance. 1 Item 11. Executive Compensation 4 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder &#160;Matters 9 Item 13. Certain Relationships and Related Transactions, and Director Independence 11 Item 14. Principal Accounting Fees and Services 13 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 14&#160; &#160; &#160; &#160;PARTIII&#160;Item 10.Directors, Executive Officers, and Corporate Governance.&#160;The following informationwith respect to our Board of Directors (the &#8220;Board&#8221;) is presented as of May 1,&#160;2023:&#160;Peter Mueller, Ph.D.,67, has served as a director of the Company since April&#160;2017 and Chairman of the Board since August&#160;2017. With over 30 yearsof global pharma and biotech experience, Dr.&#160;Mueller is currently the President of the Mueller Health Foundation, a private foundationtackling globally lethal infectious diseases such as tuberculosis by addressing latency and the ever-growing challenges of antimicrobialresistance. From 2014 to 2016, he was President of RD and Chief Scientific Officer of Axcella Health, a biotechnology company. From2003 to 2014, Dr.&#160;Mueller served as Executive Vice President Global Research and Development Chief Scientific Officer for VertexPharmaceuticals, Incorporated, a biotechnology company. He was involved in the development of Incivek (2011), Kalydeco (2012), and Orkambi(2014). Prior to his tenure at Vertex, he served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals,Inc. overseeing global research programs (immunology, inflammation, cardiovascular diseases and gene therapy) and the development of alldrug candidates of the company&#8217;s worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He was involvedin the development of Spiriva, Combivent, Atrovent and Viramune. Dr.&#160;Mueller received both an undergraduate degree and a Ph.D. inChemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. Hecompleted fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. He is a member of variousscientific and political societies and currently serves on the Board of the US-India Chamber of Commerce Biotech. He also services aschairman of the Scientific Advisory Board of BioXcel LLC and is an advisor to the University of Iowa Center for Bioanalysis and Bioprocessing.&#160;June Bray, 69,has served as a director of the Company since March&#160;2021. She previously served as Senior Vice President, Global Regulatory Affairsand Medical Writing of Allergan, Inc., a pharmaceutical company, from 2008 to 2020, where she was in charge of global regulatory strategiesfor development projects and lifecycle management for all therapeutic areas. From 2006 to 2008, Ms. Bray was Vice President, RegulatoryAffairs at Organon Co. (prior to its merger with Merck Co.), where she led departments responsible for regulatory activitiesfor development and marketed products and, from 1980 to 2006, Ms. Bray served in various capacities at Berlex Laboratories, Inc., mostrecently as Vice President, Global Regulatory Affairs for Specialized Therapeutics/Oncology, a position she held from 2003 to 2006. Ms.Bray has served on the Board of Quince Therapeutics, Inc. since June&#160;2022. Ms. Bray holds an M.B.A. from Fairleigh Dickinson Universityand a B.S.&#160;from the University of Rhode Island.&#160;Sandeep Laumas, M.D.,55, has served as a director of the Company since September&#160;2017. Since June&#160;2020, Dr.&#160;Laumas has served as Chief BusinessOfficer and Chief Financial Officer of Instil Bio Inc. He served as a Director of BioXcel Corporation from May&#160;2013 to August&#160;2017.Dr.&#160;Laumas served as a director of 9 Meters BioPharma, Inc. (formerly Innovate Biopharmaceuticals Inc.), a biopharma company, fromJanuary&#160;2014 to June&#160;2021, including serving as the Executive Chairman from 2014 to April&#160;2020, and as its Chief ExecutiveOfficer from February&#160;2019 to April&#160;2020. Dr.&#160;Laumas has served as a director of Unicycive Therapeutics Inc. since 2018.He began his career at Goldman Sachs Co. in New York in the Investment Banking Division. Dr.&#160;Laumas then joined Balyasny AssetManagement in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. Hehas been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr.&#160;Laumas has served as a director of ParkwayHoldings Ltd. (IHH Healthcare) and SRL Ltd. Dr.&#160;Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. fromAlbany Medical College in 1995 with a research gap year at the Dana- Farber Cancer Institute and completed his medical internship in 1996from the Yale University School of Medicine.&#160;Vimal Mehta, Ph.D.,62, co-founded the Company and has served as a member of our Board since April&#160;2017 and as our Chief Executive Officer and Presidentsince May&#160;2017. Dr.&#160;Mehta also served as our Corporate Secretary from May&#160;2017 to February&#160;2021. He is also the co-founderof BioXcel Corporation (now BioXcel LLC) and, following its inception in 2005 until March&#160;2023, served as its Chairman of the Boardand Chief Executive Officer. Dr.&#160;Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-DoctoralFellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr.&#160;Mehta has garnered a deepunderstanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiativesencompassing corporate strategy and planning, global business development, and corporate fundraising.&#160; 1 &#160; &#160;Michael Miller,66, has served as a director of the Company since June&#160;2022. He has served as an advisor to several biopharmaceutical companies,including Concarlo Therapeutics since June&#160;2022 and Rigel Pharmaceuticals, Inc. since January&#160;2022. Prior to that, he servedas Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March&#160;2014 to August&#160;2020. Since May&#160;2018, Mr.&#160;Millerhas served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee. Mr.&#160;Miller received his B.S.&#160;fromthe University of San Francisco and his M.B.A. from San Francisco State University.&#160;Krishnan Nandabalan,Ph.D, 60,. co-founded the Company and has served as a member of our Board since May&#160;2017. Dr.&#160;Nandabalan served as aconsultant to the Company in the capacity of Chief Digital Officer from January&#160;2020 to August&#160;2022. He is also the co-founderof BioXcel Corporation (now BioXcel LLC) and, following its inception in 2005, has served as its President, Secretary and Chief ScientificOfficer and as a member of its board of directors. Dr.&#160;Nandabalan has also served as Chief Executive Officer and a director of InveniAILLC, a wholly owned subsidiary of BioXcel LLC, since May&#160;2017 and as Chief Executive Officer and a director of Invea Therapeutics,Inc. since October&#160;2021. Dr. Nandabalan holds a B.Sc. and M.Sc. in agricultural science from Tamil Nadu Agricultural University anda Ph.D. in biochemistry and molecular biology from Indian Institute of Science.&#160;Michal Votruba, M.D.,57, has served as a director of the Company since March&#160;2019. Since 2013, Dr.&#160;Votruba has been a Director of the Gradus/RSJLife Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr.&#160;Votrubaserved as a director of Mynd Analytics, Inc., a telebehavioral health services company, from July&#160;2015 to 2019, and served as a directorof Telemynd, Inc., successor to Mynd Analytics, since 2019. Since 2010, he has served as a member of the board of PrimeCell Therapeuticsas the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in CentralEurope. In 2009, the Czech Academy of Sciences solicited Dr.&#160;Votruba&#8217;s expertise for the first successful privatization projectof the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projectsin the Czech Republic. Dr.&#160;Votruba earned his M.D. from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter,he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr.&#160;Votruba combined histheoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight yearsas an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli&#160;Lilly, Allergan, EMD, Serono and Sanofi.&#160;The following information withrespect to our executive officers is presented as of May 1, 2023:&#160;See above for Vimal Mehta&#8217;sbiography.&#160;Richard I. Steinhart,66, has served as our Senior Vice President and Chief Financial Officer since March&#160;2018. From October&#160;2017 to March&#160;2018,Mr.&#160;Steinhart served as our Vice President and Chief Financial Officer. From October&#160;2015 to June&#160;2017, he was Vice Presidentand CFO at Remedy Pharmaceuticals, Inc. From January&#160;2014 to September&#160;2015 Mr.&#160;Steinhart worked as a financial and strategicconsultant to the biotechnology and medical device industries. From April&#160;2006 through December&#160;2013, Mr.&#160;Steinhart wasemployed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April&#160;2006to April&#160;2012 and as Sr. Vice President, Finance and Chief Financial Officer from April&#160;2012 to December&#160;2013. From May&#160;1992until joining MELA Sciences, Mr.&#160;Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking,venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures,he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr.&#160;Steinhart&#8217;s other experience includesseven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a GeneralPartner and Chief Financial Officer. Mr.&#160;Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc., a positionhe assumed in November&#160;2013, and Atossa Genetics, Inc., where he began his service in March&#160;2014. Mr.&#160;Steinhart servesas the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr.&#160;Steinhartserves as the Chairman of Atossa Genetics Audit Committee and is a member of its Audit Committee and Compensation Committee. He holdsB.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).&#160; 2 &#160; &#160;Matthew Wiley,51, has served as our Senior Vice President and Chief Commercial Officer since January&#160;2022. Mr.&#160;Wiley has over 25 years ofsales, marketing, and strategy experience across multiple specialty product launches. Prior to joining the Company, Mr.&#160;Wiley servedas Chief Commercial Officer at VYNE Therapeutics, Inc., a therapeutics pharmaceutical company seeking to treat immuno-inflammatory conditions,from November&#160;2018 to September&#160;2021, where he oversaw all the commercial buildout and objectives related to the launch of thecompany&#8217;s first two approved dermatology products, AMZEEQ&#174; and ZILXI&#174;. Prior to that, he served asVice President and Business Unit Lead for Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, from 2012 to 2018 where he ledthe go-to-market strategy and marketing team for SUNOSI&#8482;, for narcolepsy and sleep apnea, and developed the successful growth strategyfor XYREM&#8482;, for narcolepsy, which achieved $1.4 billion in net revenue during his final year. He also served as Vice President ofMarketing at Azur Pharma, a specialty pharmaceutical company with a focus in central nervous system disorders, from 2007 to 2012, supportingthe company from initiation of U.S.&#160;operations through its acquisition by Jazz Pharmaceuticals. Mr.&#160;Wiley holds a B.A. fromSyracuse University in English.&#160;Frank D. Yocca, Ph.D.,67, has served as our Senior Vice President and Chief Scientific Officer since March&#160;2018. From June&#160;2017 to March&#160;2018,Dr.&#160;Yocca served as our Vice President and Chief Scientific Officer. From April&#160;2015 to April&#160;2017, he was Senior VicePresident, CNS RD of BioXcel. From 2005 to 2015, Dr.&#160;Yocca held multiple leadership roles at AstraZeneca plc, including VicePresident, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, StrategyUnit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Priorto this, he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrentleadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this, Dr.&#160;Yoccaserved as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementationof corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer&#8217;s clinicalcandidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member ofthe Early and Late Discovery and Development Teams from 1984 to 2001. Dr.&#160;Yocca holds a B.S.&#160;in biochemistry from ManhattanCollege and an M.S.&#160;in pharmacology and a Ph.D. in neuropharmacology from St. John&#8217;s University.&#160;Vincent J. O&#8217;Neill,M.D., 54, has served as our Senior Vice President and Chief Medical Officer since March&#160;2018. From July&#160;2017 to March&#160;2018,Dr.&#160;O&#8217;Neill served as our Vice President and Chief Medical Officer. He served as the Chief Medical Officer of Mirna Therapeutics,Inc. from April&#160;2016 to May&#160;2017. From June&#160;2014 to May&#160;2016, he served as the Chief Medical Officer of Exosome Diagnostics,Inc., a diagnostics company. From 2012 to 2014, Dr.&#160;O&#8217;Neill was global head of Personalized of Medicine and Companion Diagnosticsat Sanofi S.A., a pharmaceutical company. From 2009 to 2012, Dr.&#160;O&#8217;Neill served as Group Director at Genentech, Inc. wherehe was involved in the expanded approval of products such as Avastin and Tarceva. From 2006 to 2009, Dr.&#160;O&#8217;Neill served asDirector, Discovery Medicine at GlaxoSmithkline plc. Dr.&#160;O&#8217;Neill holds an M.D., MBChd and M.Sc. in Pathology from the Universityof Glasgow, UK.&#160;Javier Rodriguez,51, has served as our Senior Vice President and Chief Legal Officer and Corporate Secretary since January&#160;2021. Javier has over 20years of extensive strategic and legal experience within the biopharmaceutical industry and has broad leadership experience managing legal,compliance, corporate governance, intellectual property, data privacy, and government affairs professionals. Prior to joining BioXcelTherapeutics, he was Chief Legal Officer at Indivior PLC (LSE: INDV), a global pharmaceuticals company with operations in over 40 countries,from December&#160;2014 to December&#160;2020, where he oversaw all legal affairs, data privacy compliance, and corporate governance matters.Before taking on his role at Indivior, Javier was General Counsel at Reckitt Benckiser Pharmaceuticals Inc. where he played a key leadershiprole in negotiating and successfully effectuating the demerger and spin-off of the organization in 2014, which included closing a $750million secured term loan and $50 million revolving credit facility to fund on-going operations of the demerged entity. Earlier in hiscareer, Javier held roles of increasing responsibility at Reckitt Benckiser LLC, Bayer Healthcare Pharmaceuticals, Inc. and Berlex, Inc.He began his legal career in 2000 as a litigation associate at Thelen Reid Priest, LLP in New York City. He holds a B.S.&#160;inCivil Engineering from Rutgers University, a M.S.E. in Structural Engineering from the University of Michigan and a J.D. from the Universityof Pennsylvania.&#160; 3 &#160; &#160;CorporateGovernance&#160;Audit Committee&#160;We have a separately-designatedstanding audit committee whose current members are Peter Mueller, Sandeep Laumas, Michael Miller and Michal Votruba, with Dr. Laumas servingas chair. All members of our audit committee meet the requirements for financial literacy under the applicable Nasdaq rules and regulations.Our Board of Directors has affirmatively determined that each member of our audit committee qualifies as &#8220;independent&#8221; underNasdaq&#8217;s additional standards applicable to audit committee members and Rule 10A-3 of the Exchange Act of 1934, as amended (the&#8220;Exchange Act&#8221;) applicable to audit committee members. In addition, our Board of Directors has determined that Dr. Laumasqualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.&#160;Code of BusinessConduct and Ethics&#160;We have adopted a Code ofBusiness Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer, principalfinancial officer, principal accounting officer or controller or persons performing similar functions. A copy of our Code of BusinessConduct and Ethics is available under the &#8220;Governance&#8212;Governance Documents&#8221; section&#160;of the Investors page of ourwebsite located at www.bioxceltherapeutics.com, or by writing to our Corporate Secretary at our offices at 555&#160;Long Wharf Drive,New Haven, CT 06511. We intend to make any required disclosures regarding amendments to, or waivers of, provisions of our Code of Conducton our website rather than by filing a Current Report on Form 8-K.&#160;Item 11.Executive Compensation&#160;EXECUTIVE COMPENSATION&#160;The following is a discussionof the compensation arrangements of our named executive officers (&#8220;NEOs&#8221;). As an &#8220;emerging growth company&#8221; asdefined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section&#160;and have elected to complywith the scaled disclosure requirements applicable to emerging growth companies.&#160;Our NEOs include our principalexecutive officer and our two most highly compensated executive officers, other than our principal executive officer, for the fiscal yearended December&#160;31, 2022. These NEOs and their positions are:&#160;&#183;Vimal Mehta, Ph.D., our Chief Executive Officer and President;&#160;&#183;Javier Rodriguez, our Senior Vice President, Chief Legal Officer and Secretary; and&#160;&#183;Matthew Wiley, our Senior Vice President and Chief Commercial Officer.&#160;Summary CompensationTable&#160;The following table shows informationregarding the compensation of our NEOs for the years presented.&#160; Name and Principal Position&#160; Year&#160;&#160; Salary ($)&#160;&#160; Bonus ($)(1)&#160;&#160; Stock Awards ($)(2)&#160;&#160; Option Awards ($)(2)&#160;&#160; Non Equity Incentive Plan Compensation ($)(3)&#160;&#160; All Other Compensation ($)(4)&#160;&#160; Total ($)&#160; Vimal Mehta, Ph.D&#160; 2022&#160;&#160; &#160;944,436&#160;&#160; &#160;150,000&#160;&#160; &#160;800,592&#160;&#160; &#160;1,994,080&#160;&#160; &#160;654,662&#160;&#160; &#160;15,425&#160;&#160; &#160;4,559,195&#160; Chief Executive Officer&#160; 2021&#160;&#160; &#160;916,701&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;7,964,625&#160;&#160; &#160;483,052&#160;&#160; &#160;7,800&#160;&#160; &#160;9,372,177&#160; Javier Rodriguez&#160; 2022&#160;&#160; &#160;403,650&#160;&#160; &#160;50,000&#160;&#160; &#160;181,439&#160;&#160; &#160;398,219&#160;&#160; &#160;177,606&#160;&#160; &#160;7,625&#160;&#160; &#160;1,218,539&#160; Senior VP and Chief Legal Officer&#160; 2021&#160;&#160; &#160;334,028&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;1,543,898&#160;&#160; &#160;136,500&#160;&#160; &#160;&#8212;&#160;&#160; &#160;2,014,426&#160; Matthew Wiley&#160; 2022&#160;&#160; &#160;402,500&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;1,307,572&#160;&#160; &#160;210,000&#160;&#160; &#160;7,625&#160;&#160; &#160;1,927,697&#160; SVP and Chief Commercial Officer&#160; &#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;(1)The amounts reported reflect a one-time bonus paid to each of Dr.&#160;Mehta and Mr.&#160;Rodriguez inrecognition of the successful completion of a strategic financing for BTAI during 2022.&#160;(2)The amounts reported represent the grant date fair value of restricted stock units and stock options grantedto our NEOs as computed in accordance with Accounting Standards Codification 718, Compensation &#8212; Stock Compensation (ASC 718). Notethat the amounts reported in these columns reflect the accounting cost for these awards and do not correspond to the actual economic valuethat may be received by our NEOs from the awards. We provided information regarding the assumptions used to calculate the value of therestricted stock units and stock option awards in Note 11 to our financial statements included in our Annual Report on Form 10-K for theyear ended December&#160;31, 2022.&#160; 4 &#160; &#160;(3)The amounts reported represent annual cash bonuses earned for 2022 and paid in 2023. For additional information,see &#8220;2022 Annual Bonuses&#8221; below.&#160;(4)The amounts reported for 2022 represent reimbursement for healthcare benefits for Dr.&#160;Mehta ($7,800)and 401(k) matching contributions ($7,625) for each named executive officer.&#160;Narrative to SummaryCompensation Table&#160;2022 Salaries&#160;Our NEOs receive a base salaryto compensate them for services rendered to the Company. The base salary payable to each NEO is intended to provide a fixed componentof compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. The base salaries of our NEOs are reviewedfrom time to time and adjusted when our Board or compensation committee determines an adjustment is appropriate. In early 2022, the Boardincreased the base salaries of Dr.&#160;Mehta and Mr.&#160;Rodriguez to $944,436 and $403,650, respectively, in connection with annualmerit increases for all employees. Mr.&#160;Wiley&#8217;s annual base salary for 2022 of $420,000 was negotiated in connection with hiscommencing employment in January&#160;2022.&#160;2022 Annual Bonuses&#160;We offer our NEOs the opportunityto earn annual cash bonuses to compensate them for attaining company and individual performance goals. Each NEO&#8217;s target bonus opportunityis expressed as a percentage of annual base salary. The 2022 annual bonuses for Dr.&#160;Mehta, Mr.&#160;Rodriguez and Mr.&#160;Wileywere targeted at 55%, 40% and 40%&#160;of their respective base salaries.&#160;The performance goals forannual bonuses are reviewed and approved annually by the compensation committee. For 2022, our NEOs were eligible to earn annual bonusesbased on the achievement of certain company performance goals, which generally related to clinical trial performance, and completing certainfinancial and operational objectives, as well as an assessment of individual performance. In March&#160;2023, the Board approved the 2022annual bonuses for the NEOs following an assessment of the NEOs&#8217; individual performance and the Company&#8217;s achievement againstcompany performance goals. The actual annual cash bonuses awarded to each NEO for 2022 performance are set forth above in the SummaryCompensation Table in the column entitled &#8220;Non-Equity Incentive Plan Compensation.&#8221;&#160;Equity Compensation&#160;During 2022, we awarded stockoptions and restricted stock units to our NEOs as the long-term incentive component of our executive compensation program. We typicallygrant equity awards at such times as our Board determines appropriate. The following table sets forth the equity awards granted to ourNEOs during 2022.&#160; &#160;&#160; 2022 Equity Awards Granted (#)&#160; Name&#160; Options&#160;&#160; RSUs&#160; Vimal Mehta, Ph.D&#160; &#160;167,000&#160;&#160; &#160;56,750&#160; Javier Rodriguez&#160; &#160;33,350&#160;&#160; &#160;13,337&#160; Matthew Wiley&#160; &#160;85,000&#160;&#160; &#160;&#8212;&#160; &#160;The options were granted withexercise prices equal to the fair market value of our common stock on the date of grant. The stock options and restricted stock unitsgenerally vest over four years with 25% of the shares subject to the award vesting on the first anniversary of the date of grant and theremaining 75% of the shares subject to the award vesting, with respect to options, in substantially equal monthly installments over thefollowing thirty-six months, and with respect to restricted stock units, in substantially equal quarterly installments over the following12 quarters, subject, in each case, to the holder&#8217;s continued service through the applicable vesting date; provided that 15,000restricted stock units granted to Dr.&#160;Mehta and 5,000 restricted stock units granted to Mr.&#160;Rodriguez in 2022 vest on the firstanniversary of the date of grant.&#160; 5 &#160; &#160;Refer to the &#8220;OutstandingEquity Awards at Year End&#8221; table below for additional information regarding the equity awards we granted to our NEOs during 2022.&#160;Other Elements of Compensation&#160;Our NEOs are eligible to participatein our employee benefit plans and programs, which generally include medical, dental and vision benefits, and life, short-term, and long-termdisability insurance to the same extent as our other full-time employees generally, subject to the terms and eligibility requirementsof those plans. During 2022, we reimbursed Dr.&#160;Mehta for his healthcare premium payments.&#160;We maintain a 401(k) definedcontribution plan (the &#8220;401(k) Plan&#8221;), for the benefit of our employees who satisfy certain eligibility requirements. OurNEOs are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. In 2022, we matched employee contributionsto the 401(k) Plan up to 50% of the first 5% of eligible compensation.&#160;The amounts paid pursuantto these arrangements are set forth in the Summary Compensation Table in the column entitled &#8220;All Other Compensation.&#8221;&#160;Outstanding EquityAwards at Year End&#160;The following table sets forthall outstanding equity awards held by each of the NEOs as of December&#160;31,&#160;2022.&#160; &#160;&#160; &#160;&#160; Option Awards&#160; Stock Awards&#160; Name&#160; Vesting Commencement Date&#160; Number of Securities Underlying Unexercised Options (#) Exercisable&#160;&#160; Number of Securities Underlying Unexercised Options (#) Unexercisable&#160;&#160; Option Exercise Price ($)&#160;&#160; Option Expiration Date&#160; Number of Shares or Units of Stock That Have Not Vested (#)&#160;&#160; Market Value of Shares or Units that Have Not Vested ($)(1)&#160; Vimal Mehta, Ph.D&#160; 08/23/2017&#160; &#160;414,000&#160;&#160; &#160;&#8212;&#160;&#160; &#160;0.41&#160;&#160; 08/23/2027&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 05/23/2019&#160; &#160;187,700&#160;&#160; &#160;&#8212;&#160;&#160; &#160;10.04&#160;&#160; 05/23/2029&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 05/26/2020(2)&#160;&#160; &#160;161,458&#160;&#160; &#160;88,542&#160;&#160; &#160;45.99&#160;&#160; 05/26/2030&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 03/25/2021(2)&#160;&#160; &#160;109,374&#160;&#160; &#160;140,626&#160;&#160; &#160;41.17&#160;&#160; 03/25/2031&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 03/14/2022(3)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;167,000&#160;&#160; &#160;15.31&#160;&#160; 03/14/2032&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 03/14/2022&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#8212;&#160; &#160;41,750(4)&#160;&#160; $896,790&#160; &#160;&#160; 05/12/2022&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#8212;&#160; &#160;15,000(5)&#160;&#160; $322,200&#160; Javier Rodriguez&#160; 02/22/2021(2)&#160;&#160; &#160;14,666&#160;&#160; &#160;17,334&#160;&#160; &#160;54.90&#160;&#160; 02/22/2031&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 08/16/2021(2)&#160;&#160; &#160;3,333&#160;&#160; &#160;6,667&#160;&#160; &#160;23.84&#160;&#160; 08/16/2031&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 03/14/2022(3)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;33,350&#160;&#160; &#160;15.31&#160;&#160; 03/14/2032&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160; 03/14/2022&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#8212;&#160; &#160;8,337(4)&#160;&#160; $179,079&#160; &#160;&#160; 05/12/2022&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#8212;&#160; &#160;5,000(5)&#160;&#160; $107,400&#160; Matthew Wiley&#160; 01/17/2022(3)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;85,000&#160;&#160; &#160;18.00&#160;&#160; 01/17/2032&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; &#160;&#160;(1)The amounts shown are based on the closing price of our common stock on December&#160;30, 2022 of $21.48per share.&#160;(2)The unvested portion of the option vests in substantially equal monthly installments until the fourthanniversary of the vesting commencement date.&#160;(3)The option vests as to 25% of the shares on the first anniversary of the vesting commencement date andin substantially equal monthly installments thereafter until the fourth anniversary of the vesting commencement date.&#160;(4)The RSUs vest as to 25% of the shares on the first anniversary of the vesting commencement date and insubstantially equal quarterly installments thereafter until the fourth anniversary of the vesting commencement date.&#160;(5)The RSUs vest on the first anniversary of the vesting commencement date.&#160;Employment Arrangements&#160;We have entered into employmentagreements with each of our NEOs that set forth the terms and conditions of each executive&#8217;s employment with us. Each employmentagreement establishes an annual base salary and target bonus opportunity for each NEO. The amounts in effect during 2022 are describedabove under the headings &#8220;2022 Salaries&#8221; and &#8220;2022 Annual Bonuses.&#8221; The NEOs are eligible to participate in ouremployee benefit plans and programs for which the NEO is eligible, subject to the terms and conditions of such plans and programs.&#160; 6 &#160; &#160;During 2022, in the eventthat an NEO was terminated by us without cause, or by the executive for good reason, subject to the NEO&#8217;s timely execution and non-revocationof a release of claims in our favor, the executive would have been eligible to receive (i) a pro-rated portion of the executive&#8217;sannual bonus for the year of termination; (ii) base salary continuation for 24 months for Dr.&#160;Mehta, 6 months for Mr.&#160;Rodriguezor 9 months for Mr.&#160;Wiley; and (iii) reimbursement for COBRA premium payments for the applicable severance period. In addition, Dr.&#160;Mehtawould be entitled to vesting of 50% of any unvested equity awards held by him immediately prior to his termination. The Company must providean NEO 30 days&#8217; notice in the event we terminate such NEO without cause.&#160;The employment agreementsalso provide that, in the event an NEO&#8217;s employment is terminated by us without cause or by the NEO for good reason, in either case,within 6 months prior to or 12 months after a change in control, then, subject to the NEO&#8217;s timely execution and non-revocationof a release of claims in our favor, the NEO will be entitled to a lump sum payment equal to 6 months of base salary (or 24 months ofbase salary for Dr.&#160;Mehta), which payment is in addition to the severance payments and benefits described above.&#160;The employment agreementsgenerally define &#8220;cause&#8221; as, subject to certain notice and cure rights, the NEO&#8217;s (i) material breach or material defaultof the employment agreement or any other agreement between us and the NEO, or repeated failure to follow the direction of the Companyor our Board, as applicable; (ii) gross negligence, willful misfeasance or breach of fiduciary duty to us or our affiliates; (iii) commissionof an act or omission involving fraud, embezzlement, misappropriation or dishonesty in connection with NEO&#8217;s duties to us or ouraffiliates, or, for Mr.&#160;Rodriguez or Mr.&#160;Wiley, that is otherwise likely to be materially injurious to the business or reputationof the Company or our affiliates; or (iv) conviction of, indictment for, or pleading guilty or nolo contendere to, any felony or othercrime involving fraud or moral turpitude.&#160;The employment agreementsgenerally define &#8220;good reason&#8221; as, subject to certain notice and cure rights, the occurrence of any of the following (withoutthe NEO&#8217;s express written consent): (i) a significant reduction of the NEO&#8217;s duties, position or responsibilities, or theremoval of the NEO from such position, duties or responsibilities; (ii) for Dr.&#160;Mehta and Mr.&#160;Rodriguez only, the relocationof the NEO by more than 25 miles; or (iii) any action or inaction that constitutes a material breach by us or any of our successors ofits obligations to the NEO under the employment agreement (or for Dr.&#160;Mehta, any other agreement between us and Dr.&#160;Mehta).&#160;The employment agreementsalso contain covenants prohibiting the NEOs from competing with us or soliciting our suppliers, employees or customers during employmentand for a period of one year following termination.&#160;DIRECTOR COMPENSATION&#160;The non-employee members ofour Board are eligible to receive compensation for their service on our Board. During 2022, our Board approved certain updates to ourdirector compensation program based on an analysis provided by Radford, the company&#8217;s independent compensation consultant, comparingour director compensation levels to those of our peers. Under our director compensation program, during 2022 each non-employee directorwas eligible to receive an option to purchase 30,000 shares of common stock upon such director&#8217;s initial election or appointmentto the Board. Additionally, each non-employee directors who has been serving as a non-employee director for at least six months as ofthe date of any annual meeting of stockholders and will continue to serve as a non-employee director immediately following such meeting,was eligible to receive an option to purchase 17,000 shares of common stock on the date of such annual meeting. The options granted toour non-employee directors have an exercise price equal to the fair market value of our common stock on the date of grant and expire notlater than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest inthree substantially equal annual installments following the date of grant. The stock options granted annually to directors vest in a singleinstallment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvestedstock options vest in full upon the occurrence of a change in control.&#160; 7 &#160; &#160;In addition, our non-employeedirectors were eligible to receive cash retainers for service on our Board and committees of our Board during 2022 as set forth in thetable below.&#160; Position&#160; Amount&#160; Base Board Fee&#160; $60,000&#160; Chair of Board or Lead Independent Director&#160; $35,000&#160; Chair of Audit Committee&#160; $20,000&#160; Chair of Compensation Committee&#160; $15,000&#160; Chair of Nominating and Corporate Governance Committee&#160; $10,000&#160; Member of Audit Committee (non-Chair)&#160; $10,000&#160; Member of Compensation Committee (non-Chair)&#160; $7,500&#160; Member of Nominating and Corporate Governance Committee (non-Chair)&#160; $5,000&#160; &#160;Director fees under the programare payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendarquarter, provided that the amount of each payment will be prorated for any portion of a quarter that a director is not servingon our board.&#160;We also reimburse all of ournon-employee directors for all reasonable and customary business expenses in accordance with company policy.&#160;Director CompensationTable&#160;The following table sets forthinformation for the year ended December&#160;31, 2022 regarding the compensation awarded to, earned by or paid to our non-employee directors:&#160; Name&#160; Fees Earned or Paid in Cash ($)&#160;&#160; Option Awards ($)(1)&#160;&#160;&#160; All Other Compensation ($)&#160;&#160; Totals ($)&#160; Peter Mueller, Ph.D.&#160; &#160;120,840&#160;&#160; &#160;174,327(2)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;295,167&#160; Sandeep Laumas, M.D.&#160; &#160;90,289&#160;&#160; &#160;174,327(3)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;264,616&#160; Krishnan Nandabalan, Ph.D.(7)&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#8212;&#160;&#160;&#160; $100,000&#160;&#160; $100,000&#160; Michal Votruba, M.D.&#160; &#160;68,421&#160;&#160; &#160;174,327(4)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;242,748&#160; June Bray&#160; &#160;64,368&#160;&#160; &#160;174,327(5)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;238,695&#160; Michael Miller&#160; &#160;19,194&#160;&#160; &#160;336,057(6)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;355,251&#160; &#160;&#160;(1)The amounts reported represent the grant date fair value of stock options granted to our non-employeedirectors as computed in accordance with ASC 718. Note that the amounts reported in this column reflect the accounting cost for thesestock options and do not correspond to the actual economic value that may be received by the recipients from the options. We provide informationregarding the assumptions used to calculate the value of the option awards in Note 11 to our financial statements included in our AnnualReport on Form 10-K for the year ended December&#160;31, 2022.&#160;(2)As of December&#160;31, 2022, Dr.&#160;Mueller held options to purchase an aggregate of 232,597 sharesof our common stock, of which 215,597&#160;shares of common stock were exercisable.&#160;(3)As of December&#160;31, 2022, Dr.&#160;Laumas held options to purchase an aggregate of 190,388 sharesof our common stock, of which 173,388&#160;shares of common stock were exercisable.&#160;(4)As of December&#160;31, 2022, Dr.&#160;Votruba held options to purchase an aggregate of 66,200 sharesof our common stock, of which 49,200&#160;shares of common stock were exercisable.&#160;(5)As of December&#160;31, 2022, Ms. Bray held options to purchase an aggregate of 46,167 shares of our commonstock, of which 12,499 shares of common stock were exercisable.&#160;(6)Mr.&#160;Miller joined the board in June&#160;2022. As of December&#160;31, 2022, Mr.&#160;Miller heldoptions to purchase an aggregate of 30,000 shares of our common stock, of which no shares of common stock were exercisable.&#160;(7)Dr.&#160;Nandabalan serves as President and Chief Scientific Officer of BioXcel Corporation and did notreceive compensation for his service on our board during 2022. Until August&#160;31, 2022, Dr.&#160;Nandabalan served as a consultantto the Company in the capacity of Chief Digital Officer and amounts shown in the table above represent cash fees earned by Dr.&#160;Nandabalanfor his service to the Company in such role. See &#8220;Certain Transactions with Related Persons - Consulting Arrangements with BioXcelLLC Employees&#8221; below for additional information. As of December&#160;31, 2022, Dr.&#160;Nandabalan held options to purchase 423,688shares of our common stock, of which 423,688 shares of common stock were exercisable.&#160;Compensation CommitteeInterlocks and Insider Participation&#160;During the 2022 fiscal year,the members of our compensation committee were Drs. Laumas and Mueller, neither of whom was, during the fiscal year, an officer or employeeof the Company and neither of whom was formerly an officer of the Company. During 2022, none of our executive officers served as a memberof the board of directors or compensation committee (or other committee performing equivalent functions) of any entity that had one ormore executive officers serving on our Board or compensation committee.&#160; 8 &#160; &#160;During the fiscal year endedDecember&#160;31, 2022, no other relationships required to be disclosed by the rules of the SEC existed aside from those identified herein.&#160;Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;Security Ownershipof Certain Beneficial Owners and Management&#160;The following table sets forthinformation relating to the beneficial ownership of our common stock as of April&#160;27, 2023 by:&#160;&#183;each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstandingshares of common stock;&#160;&#183;each of our directors;&#160;&#183;each of our named executive officers for 2022; and&#160;&#183;all directors and executive officers as a group.&#160;The number of shares beneficiallyowned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a &#8220;beneficial&#8221;owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to directthe disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, thatthe individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stockbeneficially owned by them, subject to any applicable community property laws.&#160;The percentage of shares beneficiallyowned is computed on the basis of 29,159,638 shares of our common stock outstanding as of April&#160;27, 2023. Shares of our common stockthat a person has the right to acquire within 60&#160;days of April&#160;27, 2023 &#160;aredeemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstandingfor purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directorsand executive officers as a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o 555 Long WharfDrive, New Haven, CT 06511.&#160; Name of Beneficial Owner&#160; Number of Shares Beneficially Owned&#160;&#160; Percentage of Shares Beneficially Owned&#160; Holders of more than 5%:&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160; BioXcel LLC(1)&#160;&#160; &#160;8,546,750&#160;&#160; &#160;29.3% FMR LLC(2)&#160;&#160; &#160;4,203,436&#160;&#160; &#160;14.4% Adage Capital Advisors, L.L.C.(3)&#160;&#160; &#160;1,548,591&#160;&#160; &#160;5.3% Named executive officers and directors:&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160; Vimal Mehta, Ph.D.(4)&#160;&#160; &#160;962,722&#160;&#160; &#160;3.2% Javier Rodriguez(5)&#160;&#160; &#160;40,325&#160;&#160; &#160;*&#160; Matthew Wiley(6)&#160;&#160; &#160;30,104&#160;&#160; &#160;*&#160; June Bray(7)&#160;&#160; &#160;37,832&#160;&#160; &#160;*&#160; Sandeep Laumas, M.D.(8)&#160;&#160; &#160;190,388&#160;&#160; &#160;*&#160; Michael Miller(9)&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; Peter Mueller, Ph.D.(10)&#160;&#160; &#160;465,194&#160;&#160; &#160;1.6% Krishnan Nandabalan, Ph.D.(1) (11)&#160;&#160; &#160;8,850,438&#160;&#160; &#160;30.0% Michal Votruba, M.D.(12)&#160;&#160; &#160;250,575&#160;&#160; &#160;*&#160; All executive officers and directors as a group:&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160; (12&#160;individuals)(13)&#160;&#160; &#160;11,258,330&#160;&#160; &#160;35.8% &#160;&#160;&#160;*Represents less than 1%.&#160;(1)Based on a Schedule&#160;13G/A filed with the SEC on April 4, 2023 and information knownto us, BioXcel LLC and BioXcel Holdings, Inc. have shared voting power and shared dispositive power over 8,547,750 shares of our commonstock. Dr.&#160;Mehta and affiliated trusts are significant stockholders of BioXcel Holdings, Inc. Dr.&#160;Nandabalan and affiliatedtrusts are significant stockholders of BioXcel Holdings, Inc. Dr.&#160;Nandabalan also is a manager and officer of BioXcel LLC, and adirector, officer and stockholder of BioXcel Holdings, Inc. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc. Assuch, Dr.&#160;Nandabalan may be deemed to beneficially own the shares held of record by BioXcel LLC. The address of BioXcel LLC and BioXcelHoldings, Inc. is 2614 Boston Post Road Suite 33B, Guilford, CT 06437.&#160; 9 &#160; &#160;(2)Based solely on a Schedule&#160;13G/A filed with the SEC on February&#160;9, 2023, FMR LLC beneficiallyowns 4,203,436 shares of our common stock, including sole voting power over 1,772,374 shares and sole dispositive power over 4,203,436shares; Abigail P. Johnson has sole dispositive power over 4,203,436 shares and Fidelity Growth Company Fund has sole voting power over1,772,374&#160;shares. The address for FMR LLC, Abigail P. Johnson and Fidelity Growth Company Fund is 245 Summer Street, Boston, Massachusetts02210.&#160;(3)Based solely on a Schedule&#160;13G filed with the SEC on February&#160;2, 2023, Adage Capital Partners,L.P. beneficially owns 1,548,591 shares of our common stock. Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C, RichardAtchinson and Phillip Gross each have shared voting power and shared dispositive power over 1,548,591 shares of our common stock. Theaddress for Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C., Robert Atchinson and PhillipGross is 200 Clarendon Street, Boston, Massachusetts 02116.&#160;(4)Represents for Dr.&#160;Mehta: (i) 17,894 shares of common stock (ofwhich 2,000 shares are owned jointly with Dr.&#160;Mehta&#8217;s spouse); (ii)&#160;options to purchase 927,219 shares of our common stockthat can be exercised within 60 days of April 27, 2023 and (iii) 17,609 RSUs that vest within 60 days of April 27, 2023.&#160;(5)Represents for Mr.&#160;Rodriguez: (i) 1,134 shares of common stock,(ii) options to purchase 33,670 shares of our common stock that can be exercised within 60 days of April 27, 2023 and (iii) 5,521 RSUsthat vest within 60 days of April 27, 2023.&#160;(6)Represents for Mr.&#160;Wiley options to purchase 30,104 shares of our common stock that can be exercisedwithin 60 days of April 27, 2023.&#160;(7)Represents for Ms. Bray options to purchase 37,832 shares of our common stock that can be exercised within60 days of April 27, 2023.&#160;(8)Represents for Dr.&#160;Laumas options to purchase 190,388 shares of our common stock that can be exercisedwithin 60 days of April 27, 2023.&#160;(9)Mr.&#160;Miller does not beneficially own any shares of our common stock.&#160;(10)Includes for Dr.&#160;Mueller 90,000 shares of our common stock held by the Peter Mueller 2018 IrrevocableFamily Trust, as to which Dr.&#160;Mueller serves as trustee, and options to purchase 232,597 shares of our common stock that can be exercisedwithin 60 days of April 27, 2023.&#160;(11)In addition to shares described in footnote (1), includes for Dr.&#160;Nandabalan options to purchase303,688 shares of our common stock that can be exercised within 60 days of April 27, 2023.&#160;(12)Includes 184,375 shares of our common stock held by RSJ Investments SICAV a.s. (&#8220;RSJ/Gradus&#8221;)and over which Dr.&#160;Votruba, an asset manager at RSJ/Gradus, has voting and/or dispositive power. Also includes options to purchase66,200 shares of our common stock that can be exercised within 60 days of April 27, 2023, which options Dr.&#160;Votruba was granted inrespect of his service on our Board but as to which he assigned to RSJ/Gradus pursuant to the policies of RSJ/Gradus regarding stock ownershipby employees.&#160;(13)Includes (i) options to purchase 2,233,652 shares of our common stockthat can be exercised within 60 days of April 27, 2023 and (ii) 29,693 RSUs that vest within 60 days of April 27, 2023.&#160;Equity CompensationPlan Information&#160;The following table providescertain information with respect to the Company&#8217;s equity compensation plans in effect as of December&#160;31, 2022:&#160; Plan Category&#160; Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)&#160;&#160; Weighted-average exercise price of outstanding options, warrants and rights (b)&#160;&#160; Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))(4) (c)&#160; Equity compensation plans approved by security holders(1)&#160;&#160; &#160;5,001,351(2)&#160;&#160; $17.23(3)&#160;&#160; &#160;1,223,219&#160; Equity compensation plans not approved by security holders&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; TOTAL&#160; &#160;5,001,351&#160;&#160; $17.23&#160;&#160; &#160;1,223,219&#160; &#160;&#160;(1)Consists of the BioXcel Therapeutics, Inc. 2017 Incentive Award Plan (the &#8220;2017 Plan&#8221;), theBioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) and the BioXcel Therapeutics, Inc. 2020 Employee StockPurchase Plan (the &#8220;2020 ESPP&#8221;).&#160;(2)Includes 2,260,621 outstanding options to purchase shares under the 2017 Plan, 119,268 restricted stockunits and 2,621,462 outstanding options to purchase shares under the 2020 Plan.&#160;(3)As of December&#160;31, 2022, the weighted-average exercise price of outstanding options under the 2017Plan was $3.62 and the weighted-average exercise price of outstanding options under the 2020 Plan was $28.98. The weighted average exerciseprice of outstanding awards does not take into account the shares issuable upon vesting of outstanding restricted stock units which haveno exercise price.&#160; 10 &#160; &#160;(4)Includes 599,244 shares available for future issuance under the 2020 Plan and 623,975 shares availablefor issuance under the 2020 ESPP. Following the effective date of the 2020 Plan, we ceased making grants under the 2017 Plan. To the extentoutstanding awards under the 2017&#160;Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards willbe available for issuance under the 2020&#160;Plan. The 2020 Plan provides for an annual increase to the number of shares available forissuance thereunder on the first day of each calendar year beginning on January&#160;1, 2021 and ending on and including January&#160;1,2030, by an amount equal to the lesser of (i)&#160;4% of the aggregate number of shares of common stock outstanding on the final day ofthe immediately preceding calendar year and (ii)&#160;such smaller number of shares of common stock as determined by our board of directors(but no more than 10,000,000 shares may be issued upon the exercise of incentive stock options). The 2020 ESPP provides for an annualincrease to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January&#160;1,2021 and ending on and including January&#160;1, 2030, by an amount equal to the lesser of (i)&#160;1% of the aggregate number of sharesof common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;such smaller number of shares ofcommon stock as is determined by our board of directors, provided that no more than 500,000 shares of our common stock may be issuedunder the component of the 2020 ESPP that is intended to qualified under Section&#160;423 of the Code.&#160;Item 13.Certain Relationships and Related Transactions, and Director Independence&#160;Policies and Procedureson Transactions with Related Persons&#160;Our Board of Directors recognizesthat transactions with related persons present a heightened risk of conflicts of interests and/or improper valuation (or the perceptionthereof). Our Board has adopted a written policy on transactions with related persons, which requires that our audit committee approveor ratify related person transactions required to be disclosed pursuant to Item 404(a). Item 404 of Regulation S-K requires disclosure,subject to certain exceptions, of transactions in which we were or are to be a participant and the amount involved exceeds $120,000 (orsuch other amount is applicable while we remain a smaller reporting company) and in which any &#8220;related person&#8221; as definedunder Item 404(a) of Regulation S-K had or will have a direct or indirect material interest. It is our policy that directors interestedin a related person transaction will recuse themselves from any vote on a related person transaction in which they have an interest andthat no director may participate in the approval of a related person transaction for which he or she is a &#8220;related person.&#8221;Each of the transactions described below entered into following the adoption of our related person transaction policy was approved inaccordance with such policy.&#160;BioXcel LLC&#160;BioXcel LLC owned approximately29.3% of the shares of our outstanding common stock as of April 27,&#160;2023. BioXcel LLC is the successor in interest to BioXcel Corporation,our former parent. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc. Vimal Mehta and affiliated trusts are significantstockholders of BioXcel Holdings, Inc. and was previously a member of the board of managers and an officer of BioXcel LLC and a directorand officer of BioXcel Holdings, Inc. Dr.&#160;Nandabalan and affiliated trusts are significant stockholders of BioXcel Holdings, Inc.Dr.&#160;Nandabalan is also a manager and officer of BioXcel LLC, and a director, officer and stockholder of BioXcel Holdings, Inc.&#160;Amendedand Restated Asset Contribution Agreement with BioXcel LLC&#160;We entered into an asset contributionagreement, effective June&#160;30, 2017, with BioXcel LLC (formerly BioXcel Corporation), as amended and restated on November&#160;7,2017 (the &#8220;Contribution Agreement&#8221;), pursuant to which BioXcel LLC contributed to us, and we acquired from BioXcel LLC, allof BioXcel LLC&#8217;s rights, title and interest in and to BXCL501, BXCL701, BXCL502 and BXCL702 (collectively, the &#8220;Candidates&#8221;)and all of the assets and liabilities associated with the Candidates, in consideration for (i) 9,480,000 shares of our common stock, (ii)&#160;$1million upon completion of our initial public offering (&#8220;IPO&#8221;), (iii) $500,000 upon the later of the 12 month anniversaryof our IPO and the first dosing of a patient in the bridging bioavailability/bioequivalence study for the BXCL501 program, (iv) $500,000upon the later of the 12 month anniversary of our IPO and the first dosing of a patient in the Phase 2 Proof of Concept open label monotherapyor combination trial with Keytruda for the BXCL701 program and (v) a one-time payment of $5 million within 60 days after the achievementof $50 million in cumulative net sales of any product or combination of products resulting from the development and commercializationof any one of the Candidates or a product derived therefrom. There were no such payments during the years ended December&#160;31, 2021or 2022 pursuant to such provisions in the Contribution Agreement.&#160;In addition, pursuant to theContribution Agreement, BioXcel LLC granted us a first right to negotiate exclusive rights to any additional product candidates in thefields of neuroscience and immuno-oncology (the &#8220;Option Field&#8221;) that BioXcel LLC may identify on its own, excluding the Candidates,and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement as defined and described below.This first right to negotiate an exclusivity period expired on March&#160;12, 2023.&#160; 11 &#160; &#160;Amended and RestatedSeparation and Shared Services Agreement&#160;We entered into a separationand shared services agreement, dated June&#160;30, 2017, or the Effective Date, with BioXcel LLC (formerly BioXcel Corporation), as amendedand restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which services provided by BioXcel LLC through its subsidiariesin India and the United States will continue indefinitely, as agreed upon by the parties. These services are primarily for drug discovery,chemical, manufacturing and controls cost and general and administrative support. Service charges recorded under this agreement were $1.4million for the years ended December&#160;31, 2022 and 2021, respectively.&#160;Under the Services Agreement,the Company has an option, exercisable through December&#160;31, 2024, to enter into a collaborative services agreement with BioXcel LLCpursuant to which BioXcel LLC shall perform product identification and related services for us utilizing EvolverAI. The Company has agreedto pay BioXcel LLC $18 per month, prorated for any partial month, as applicable, for the period beginning March&#160;13, 2023 and endingDecember&#160;31, 2024 as consideration for the option. The parties are obligated to negotiate the collaborative services agreement ingood faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royaltyon net sales and reasonable development and commercialization milestone payments, provided that (i) development milestones shallnot exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestones shallbe based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.BioXcel LLC shall continue to make such product identification and related services available to us for at least until September&#160;30,2024.&#160;Trademark License Agreement&#160;On April&#160;19, 2022, weentered into the BioXcel Trademark License Agreement, pursuant to which BioXcel LLC granted us a royalty-free license to use the BIOXCELtrademark in connection with marketing, promoting and selling any products and services in the field of neuroscience, for which the Companypaid BioXcel LLC a one-time fee of $135,000.&#160;Consulting Arrangementswith BioXcel LLC Employees&#160;From January&#160;2020 toAugust&#160;31, 2022, Krishnan Nandabalan, Ph.D., a director on our Board, was engaged as a consultant in the capacity of Chief DigitalOfficer. In connection with this service, Dr.&#160;Nandabalan was granted an option to purchase 15,000 shares of our common stock havinga value of approximately $142,800. In addition, in accordance with the Amended Services Agreement, the Company pays BioXcel LLC, whereDr.&#160;Nandabalan serves as President, monthly compensation of $12,500 in an annual aggregate amount not to exceed $150,000 as considerationunder the Services Agreement for Dr.&#160;Nandabalan&#8217;s services as Chief Digital Officer, the full amount of which was paid forthe years ended December&#160;31, 2021. In the year ended December&#160;31, 2022, Dr.&#160;Nandabalan was paid $100,000 for his servicesas Chief Digital Officer.&#160;InveniAI&#160;InveniAI, a wholly owned subsidiaryof BioXcel LLC, has agreed to provide certain research and development services to the Company in connection with our product candidatesup to a maximum aggregate amount of $300,000, $150,000 of which was paid in the year ended December&#160;31, 2021.&#160;Director and OfficerIndemnification and Insurance&#160;We have agreed to indemnifyeach of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#8217; andofficers&#8217; liability insurance.&#160;Director Independence&#160;Under our Corporate GovernanceGuidelines and Nasdaq rules, a director is independent if he or she does not have a material or other disqualifying relationship withus that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities as a director.In addition, the director must meet the bright-line tests for independence set forth by the Nasdaq rules.&#160; 12 &#160; &#160;Our Board has undertaken areview of its composition, the composition of its committees and the independence of our directors and considered whether any directorhas a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or herresponsibilities. Based upon information requested from and provided by each director concerning his or her background, employment andaffiliations, including family relationships, our Board of Directors has determined that none of Ms. Bray, Mr.&#160;Miller or Drs. Laumas,Mueller or Votruba, representing five of our seven directors, has a relationship that would interfere with the exercise of independentjudgment in carrying out the responsibilities of a director and that each of these directors qualifies as &#8220;independent&#8221; asthat term is defined under the Nasdaq rules. In making these determinations, our Board of Directors considered the relationships thateach non-employee director has with us and all other facts and circumstances our Board of Directors deemed relevant in determining theirindependence, including the director&#8217;s beneficial ownership of our common stock and the relationships of our non-employee directorswith certain of our significant stockholders.&#160;In addition, our Board ofDirectors has affirmatively determined that each member of our Audit Committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;sadditional standards applicable to audit committee members and Rule 10A-3 of the Exchange Act applicable to audit committee members. OurBoard has also determined that each member of our Compensation Committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additionalstandards applicable to compensation committee members and is a &#8220;non-employee director&#8221; as defined in Section&#160;16b-3 ofthe Exchange Act.&#160;Item 14.Principal Accounting Fees and Services&#160;Audit,Audit-Related, Tax and All Other Fees&#160;The table below sets forth theaggregate fees billed to us for services related to the fiscal year ended December&#160;31, 2022 and 2021 by Ernst Young LLP.&#160; &#160;&#160; Year Ended December&#160;31,&#160; &#160;&#160; 2022&#160;&#160; 2021&#160; Audit Fees(1)&#160;&#160; $1,569,000&#160;&#160; $484,480&#160; Audit-Related Fees&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; Tax Fees&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; All Other Fees&#160; &#160;&#8212;&#160;&#160; &#160;&#8212;&#160; TOTAL&#160; $1,569,000&#160;&#160; $484,480&#160; &#160;&#160;(1)Audit fees consisted of audit services performed in connection with the audit of the Company&#8217;s consolidatedfinancial statements, the reviews of the Company&#8217;s interim condensed consolidated financial statements, and related services thatare normally provided in connection with registration statements. Included in the 2022 and 2021 audit fees are $170,000 and $130,000,respectively, billed in connection with our follow-on offerings. 2022 audit fees also include fees related to the audit and review ofthe registration statements of the Company&#8217;s subsidiary, OnkosXcel Therapeutics LLC, of $904,200.&#160;Pre-Approval Policiesand Procedures&#160;Consistent with SEC policiesand guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-auditservices provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee has established apolicy regarding approval of all audit and permissible non-audit services provided by our principal accountants. No non-audit serviceswere performed by our independent registered public accounting firm during the years ended December&#160;31,&#160;2022 and 2021. Our AuditCommittee pre-approves these services by category and service. Our Audit Committee pre-approved all of the above-described services.&#160; 13 &#160; &#160;Item 15.Exhibits, Financial Statement Schedules&#160;Exhibits&#160;Exhibit Number &#160;Description &#160;Form &#160;File No. &#160;Exhibit &#160;Filing Date &#160;Filed/ Furnished Herewith31.1 &#160;Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;*&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160;31.2 &#160;Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;*&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160;104 &#160;Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document.) &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;*&#160; 14 &#160; &#160;SIGNATURES&#160;Pursuant to the requirementsof Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalfby the undersigned thereunto duly authorized.&#160;Dated: May 1, 2023BIOXCEL THERAPEUTICS, INC.&#160;&#160;&#160;By:/s/ Vimal Mehta&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Vimal Mehta, Ph.D.&#160;Chief Executive Officer&#160;(Principal Executive Officer)&#160; 15 &#160;"
}